Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA gyrase is an essential bacterial enzyme classified as a type II topoisomerase. It catalyzes the ATP-dependent introduction of negative supercoils into double-stranded, closed-circular DNA, a function unique among topoisomerases. This activity is critical for managing DNA topology during processes such as replication and transcription in bacteria. The enzyme is a heterotetramer composed of two GyrA and two GyrB subunits. GyrA subunit is responsible for binding and encapsulating DNA; contains the active site tyrosine. GyrB subunit contains ATP-binding and hydrolysis sites. Essential in all bacteria but absent from higher eukaryotes—making it an attractive target for antibacterial drugs such as fluoroquinolones. These drugs inhibit gyrase activity either by stabilizing cleavage complexes or blocking enzymatic function directly. Resistance development has prompted ongoing research into new inhibitors targeting different aspects or conformations within its catalytic cycle.
Fluoroquinolones inhibit gyrase activity either by stabilizing cleavage complexes or blocking enzymatic function directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Gyrase (Bacterial Type II Topoisomerase) (DNA Gyrase).